Trial Profile
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2023
Price :
$35
*
At a glance
- Drugs Zastumotide (Primary) ; AS15
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PREDICT
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 03 May 2019 This trial has been completed in France according to European Clinical Trials Database record.
- 21 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Dec 2014 Planned End Date changed from 1 Jun 2016 to 1 Feb 2015, according to the ClinicalTrials.gov record.